Amicus Therapeutics Is Offering Quality Therapies For Rare And Orphan Diseases

In America, the biotechnology industry is becoming highly competitive. Many biopharmaceutical companies are delivering quality therapies. However, only those that have the necessary resources and tools are thriving. Amicus Therapeutics is one of the leading biotechnology companies that are standing out in the industry. Amicus Therapeutics focuses on developing viable therapies for rare and orphan diseases, with a special attention to lysosomal storage disorders. Their broad portfolio of therapies targets various human genetic diseases. The company’s lead product candidate, migalastat, is a customized treatment that is in its late-stage of development. The drug targets patients diagnosed with Fabry disease based on their genetics.

Amicus Therapeutics’ SD-101, a product candidate, is also in the late-stage of development. It is a potential first-to-market drug for Epidermolysis Bullosa (EB). Their product development is largely based on Chaperone-Advanced Replacement Therapy (CHART™) platform technologies where they concentrate on the development of enzyme replacement therapies (ERT). In 2014, Amicus Therapeutics stood out as the company with “the broadest portfolio of small molecule pharmacological chaperones” in the industry. The company went public in 2007. Soon after, they expanded their operations by establishing their second research site in San Diego. Over the years, the corporation has received funding from the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation to enhance their research activities. Amicus Therapeutics has registered steady growth, including the acquisition of Callidus Biopharma and Scioderm (http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/).

The organization’s success in the highly competitive industry is an indicator of its exceptional leadership that promotes invention and healing. Amicus Therapeutics has achieved much growth under the leadership of John F. Crowley, the chairman and chief executive officer. Bradley has a sound background in the biotechnology industry. He has held high-ranking positions at Bristol-Myers Squibb, Novazyme Pharmaceuticals, and Genzyme Therapeutics. He graduated with a B.S. degree in foreign service from Georgetown University and earned a J.D. from the University of Notre Dame Law School. In addition, Crowley holds an MBA from Harvard University (YahooFinance). Crowley works closely with President and Chief Operating Officer Bradley L. Campbell to ensure that Amicus Therapeutics achieves its goals of developing quality therapies. With over 15 years of experience in the orphan drug industry, Bradley uses his vast knowledge to oversee the strategy, design and leadership of the company’s global commercial operations.

twitter